ネブラスカ州における乳がんの臨床試験
ネブラスカ州内の拠点で、乳がんに関する25件の研究が参加者を募集しています。
ネブラスカ州内の都市
公式研究テキスト（英語）
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Nebraska Cancer Specialists, Omaha
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Research Site, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07205822Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Alegent Health Immanuel Medical Center, Omaha
- 他2件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Cancer Partners of Nebraska, Lincoln
- Nebraska Cancer Specialists, Omaha
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07102381A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Cancer Partners of Nebraska ( Site 0068), Lincoln
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07007559ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Oncology Hematology West, PC dba Nebraska Cancer Specialist, Grand Island
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Nebraska Cancer Specialists, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- NHO Revive Research Institute LLC, Lincoln
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
- University of Nebraska Medical Center, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Nebraska Cancer Specialists, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Nebraska Cancer Specialists, Grand Island
- Nebraska Cancer Specialists, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Saint Francis, Grand Island
- Mary Lanning Memorial Hospital, Hastings
- 他7件
被験者募集中第3相
18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Nebraska Cancer Specialists, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
- Nebraska Cancer Specialists, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07660055Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Nebraska Cancer Specialists, Omaha
- Nebraska Medicine - University of Nebraska Medical Center, Omaha
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/08/06更新 · NCT05232916E-Mindfulness Approaches for Living After Breast Cancer
- CHI Health Good Samaritan, Kearney
被験者募集中第3相
18歳〜50歳 · 全性別 · 2026/08/04更新 · NCT06748222A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- 他3件
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/11更新 · NCT05283330ERAS Protocols in Breast Conserving Surgery
- University of Nebraska Medical Center, Omaha
被験者募集中
19歳以上 · 全性別 · 2026/05/19更新 · NCT06938581De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Good Samaritan, Kearney
- Cancer Partners of Nebraska, Lincoln
- 他2件
被験者募集中第3相
50歳〜70歳 · 全性別 · 2026/04/23更新 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- CHI Health Good Samaritan, Kearney
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
- Biotheryx Investigative Site, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2025/06/06更新 · NCT06515470CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Nebraska Methodist, Omaha
被験者募集中観察研究
18歳以上 · 女性 · 2025/01/07更新 · NCT06230185ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。